Skip to main content
main-content
Erschienen in: Endocrine 2/2020

16.03.2020 | Original Article

Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases

verfasst von: C. Happel, W. T. Kranert, D. Gröner, B. Bockisch, A. Sabet, I. Vardarli, R. Görges, K. Herrmann, F. Grünwald

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Radioiodine-131 treatment has been a well-established therapy for benign thyroid diseases for more than 75 years. However, the physiological reasons of the so-called stunning phenomenon, defined as a reduced radioiodine uptake after previous diagnostic radioiodine administration, are still discussed controversially. In a recent study, a significant dependence of thyroid stunning on the pre-therapeutically administered radiation dose could be demonstrated in patients with goiter and multifocal autonomous nodules. A release of thyroid hormones to the blood due to radiation-induced destruction of thyroid follicles leading to a temporarily reduced cell metabolism was postulated as possible reason for this indication-specific stunning effect. Therefore, the aim of this study was to develop dose-dependent correction factors to account for stunning and thereby improve precision of radioiodine treatment in these indications.

Methods

A retrospective analysis of 313 patients (135 with goiter and 178 with multifocal autonomous nodules), who underwent radioiodine uptake testing and radioiodine treatment, was performed. The previously determined indication-specific values for stunning of 8.2% per Gray in patients with multifocal autonomous nodules and 21% per Gray in patients with goiter were used to modify the Marinelli equation by the calculation of correction factors for hyperfunctioning radiation-induced stunning (CHRIS). Subsequently, the calculation of the required activity of radioiodine-131 to obtain an intra-therapeutic target dose of 150 Gy was re-evaluated in all patients. Furthermore, a calculation of the hypothetically received target dose by using the CHRIS-calculated values was performed and compared with the received target doses.

Results

After integrating the previously obtained results for stunning, CHRIS-modified Marinelli equations could be developed for goiter and multifocal autonomous nodules. For patients with goiter, the mean value of administered doses calculated with CHRIS was 149 Gy and did not differ from the calculation with the conventional Marinelli equation of 152 Gy with statistical significance (p = 0.60). However, the statistical comparison revealed a highly significant improvement (p < 0.000001) of the fluctuation range of the results received with CHRIS. Similar results were obtained in the subgroup of patients with multifocal autonomous nodules. The mean value of the administered dose calculated with the conventional Marinelli equation was 131 Gy and therefore significantly below the CHRIS-calculated radiation dose of 150 Gy (p < 0.05). Again, the fluctuation range of the CHRIS-calculated radiation dose in the target volume was significantly improved compared with the conventional Marinelli equation (p < 0.000001).

Conclusions

With the presented CHRIS equation it is possible to calculate a required individual stunning-independent radioiodine activity for the first time by only using data from the radioiodine uptake testing. The results of this study deepen our understanding of thyroid stunning in benign thyroid diseases and improve precision of dosimetry in radioiodine-131 therapy of goiter and multifocal autonomous nodules.
Literatur
1.
Zurück zum Zitat R.W. Rawson, J.E. Rall, W. Peacock, Limitations in the treatment of cancer of the thyroid with radioactive iodine. Trans. Assoc. Am. Physicians 64, 179–198 (1951) PubMed R.W. Rawson, J.E. Rall, W. Peacock, Limitations in the treatment of cancer of the thyroid with radioactive iodine. Trans. Assoc. Am. Physicians 64, 179–198 (1951) PubMed
2.
Zurück zum Zitat I.R. McDougall, A. Iagaru, Thyroid stunning: fact or fiction? Semin. Nucl. Med. 41, 105–112 (2011) PubMed I.R. McDougall, A. Iagaru, Thyroid stunning: fact or fiction? Semin. Nucl. Med. 41, 105–112 (2011) PubMed
3.
Zurück zum Zitat C. Happel, W.T. Kranert, H. Ackermann, I. Binse, B. Bockisch, D. Gröner, K. Herrmann, F. Grünwald, Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases. Endocrine 63, 537–544 (2019) PubMed C. Happel, W.T. Kranert, H. Ackermann, I. Binse, B. Bockisch, D. Gröner, K. Herrmann, F. Grünwald, Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases. Endocrine 63, 537–544 (2019) PubMed
4.
Zurück zum Zitat S. Hertz, A. Roberts, W.T. Salter, The metabolism of iodine in Graves’ disease. J. Clin. Investig. 21, 25–29 (1942) PubMed S. Hertz, A. Roberts, W.T. Salter, The metabolism of iodine in Graves’ disease. J. Clin. Investig. 21, 25–29 (1942) PubMed
5.
Zurück zum Zitat M. Medvedec, Thyroid stunning in vivo and in vitro. Nucl. Med. Commun. 26, 731–735 (2005) PubMed M. Medvedec, Thyroid stunning in vivo and in vitro. Nucl. Med. Commun. 26, 731–735 (2005) PubMed
6.
Zurück zum Zitat L.F. Morris, A.D. Waxman, G.D. Braunstein, Thyroid stunning. Thyroid 13, 333–340 (2003) PubMed L.F. Morris, A.D. Waxman, G.D. Braunstein, Thyroid stunning. Thyroid 13, 333–340 (2003) PubMed
7.
Zurück zum Zitat H.M. Park, Stunned thyroid after high-dose I-131 imaging. Clin. Nucl. Med. 17, 501–502 (1992) PubMed H.M. Park, Stunned thyroid after high-dose I-131 imaging. Clin. Nucl. Med. 17, 501–502 (1992) PubMed
8.
Zurück zum Zitat S.P. Cholewinski, K.S. Yoo, P.S. Klieger, R.E. O’Mara, Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J. Nucl. Med. 41, 1198–1202 (2000) PubMed S.P. Cholewinski, K.S. Yoo, P.S. Klieger, R.E. O’Mara, Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J. Nucl. Med. 41, 1198–1202 (2000) PubMed
9.
Zurück zum Zitat A.J. Coakley, Thyroid stunning. Eur. J. Nucl. Med. 25, 203–204 (1998) PubMed A.J. Coakley, Thyroid stunning. Eur. J. Nucl. Med. 25, 203–204 (1998) PubMed
10.
Zurück zum Zitat H.Q. Dam, S.M. Kim, H.C. Lin, C.M. Intenzo, 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 232, 527–533 (2004) PubMed H.Q. Dam, S.M. Kim, H.C. Lin, C.M. Intenzo, 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 232, 527–533 (2004) PubMed
11.
Zurück zum Zitat P. Postgård, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nyström, E. Forssell-Aronsson, M. Nilsson, Stunning of iodide transport by 131i irradiation in cultured thyroid epithelial cells. J. Nucl. Med. 43, 828–834 (2002) PubMed P. Postgård, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nyström, E. Forssell-Aronsson, M. Nilsson, Stunning of iodide transport by 131i irradiation in cultured thyroid epithelial cells. J. Nucl. Med. 43, 828–834 (2002) PubMed
12.
Zurück zum Zitat M.M. Nordén, F. Larsson, S. Tedelind, T. Carlsson, C. Lundh, E. Forssell-Aronsson, M. Nilsson, Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res. 67, 7512–7517 (2007) PubMed M.M. Nordén, F. Larsson, S. Tedelind, T. Carlsson, C. Lundh, E. Forssell-Aronsson, M. Nilsson, Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res. 67, 7512–7517 (2007) PubMed
13.
Zurück zum Zitat B. Meller, E. Gaspas, W. Deisting, B. Czarnocka, M. Baehre, B.E. Wenzel, Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway. Eur. J. Nucl. Med. Mol. Imaging 35, 1204–1212 (2008) PubMed B. Meller, E. Gaspas, W. Deisting, B. Czarnocka, M. Baehre, B.E. Wenzel, Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway. Eur. J. Nucl. Med. Mol. Imaging 35, 1204–1212 (2008) PubMed
14.
Zurück zum Zitat M. Perona, L. Thomasz, L. Rossich, C. Rodriguez, M.A. Pisarev, G. Rosemblit, G.A. Cremaschi, M.A. Dagrosa, G.J. Juvenal, Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone decetylase sodium butyrate and valproic acid. Mol. Cell. Endocrinol. 478, 141–150 (2018) PubMed M. Perona, L. Thomasz, L. Rossich, C. Rodriguez, M.A. Pisarev, G. Rosemblit, G.A. Cremaschi, M.A. Dagrosa, G.J. Juvenal, Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone decetylase sodium butyrate and valproic acid. Mol. Cell. Endocrinol. 478, 141–150 (2018) PubMed
15.
Zurück zum Zitat C. Challeton, F. Branea, M. Schlumberger, N. Gaillard, F. DeVathaire, C. Badie, P. Antonini, C. Parmentier, Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int. J. Radiat. Oncol. Biol. Phys. 37, 163–169 (1997) PubMed C. Challeton, F. Branea, M. Schlumberger, N. Gaillard, F. DeVathaire, C. Badie, P. Antonini, C. Parmentier, Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int. J. Radiat. Oncol. Biol. Phys. 37, 163–169 (1997) PubMed
16.
Zurück zum Zitat A. Gaussen, J.D. Legal, N. Beron-Gaillard, A. Laplanche, J.P. Travagli, B. Caillou, C. Parmentier, Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay. Int. J. Radiat. Biol. Phys. 44, 683–691 (1999) A. Gaussen, J.D. Legal, N. Beron-Gaillard, A. Laplanche, J.P. Travagli, B. Caillou, C. Parmentier, Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay. Int. J. Radiat. Biol. Phys. 44, 683–691 (1999)
17.
Zurück zum Zitat R.T. Mulcahy, M.N. Gould, K.H. Clifton, The survival of thyroid cells: in vivo irradiation and in situ repair. Radiat. Res. 84, 523–528 (1980) PubMed R.T. Mulcahy, M.N. Gould, K.H. Clifton, The survival of thyroid cells: in vivo irradiation and in situ repair. Radiat. Res. 84, 523–528 (1980) PubMed
18.
Zurück zum Zitat W. Brenner, Is thyroid Stunning a real Phenomenon or just fiction? J. Nucl. Med. 43, 835–836 (2002) PubMed W. Brenner, Is thyroid Stunning a real Phenomenon or just fiction? J. Nucl. Med. 43, 835–836 (2002) PubMed
19.
Zurück zum Zitat W. Koch, P. Knesewitsch, K. Tatsch, K. Hahn, Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out. Nuklearmedizin 42, 10–14 (2003) PubMed W. Koch, P. Knesewitsch, K. Tatsch, K. Hahn, Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out. Nuklearmedizin 42, 10–14 (2003) PubMed
20.
Zurück zum Zitat H.M. Park, Y.H. Park, X.H. Zhou, Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 7, 277–280 (1997) PubMed H.M. Park, Y.H. Park, X.H. Zhou, Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 7, 277–280 (1997) PubMed
21.
Zurück zum Zitat J.F. Malone, The radiation biology of the thyroid. Curr. Top. Radiat. Res. Q. 10, 263–368 (1975) PubMed J.F. Malone, The radiation biology of the thyroid. Curr. Top. Radiat. Res. Q. 10, 263–368 (1975) PubMed
22.
Zurück zum Zitat M. Dietlein, W. Eschner, M. Lassmann, H. Hänscheid, F.A. Verburg, M. Luster, DGN-Handlungsempfehlung (S1-Leitlinie): Radioiodtest (Version 4). Stand 10/2014 - AWMF-Registernummer: 031-012 (2014) M. Dietlein, W. Eschner, M. Lassmann, H. Hänscheid, F.A. Verburg, M. Luster, DGN-Handlungsempfehlung (S1-Leitlinie): Radioiodtest (Version 4). Stand 10/2014 - AWMF-Registernummer: 031-012 (2014)
23.
Zurück zum Zitat M. Dietlein, F. Grünwald, M. Schmidt, P. Schneider, F.A. Verburg, M. Luster, Radioiodine therapy for benign thyroid disease (version 5). German Guideline. Nuklearmedizin 55, 213–220 (2016) PubMed M. Dietlein, F. Grünwald, M. Schmidt, P. Schneider, F.A. Verburg, M. Luster, Radioiodine therapy for benign thyroid disease (version 5). German Guideline. Nuklearmedizin 55, 213–220 (2016) PubMed
24.
Zurück zum Zitat L.D. Marinelli, Dosage determination in the use of radioactive isotopes. J. Clin. Investig. 28, 1271–1280 (1949) PubMed L.D. Marinelli, Dosage determination in the use of radioactive isotopes. J. Clin. Investig. 28, 1271–1280 (1949) PubMed
25.
Zurück zum Zitat C. Happel, W.T. Kranert, B. Bockisch, H. Korkusuz, F. Grünwald, 131I- and 99mTc-uptake in focal thyroid autonomies. Development in Germany since the 1980s. Nuklearmedizin 55, 236–241 (2016) PubMed C. Happel, W.T. Kranert, B. Bockisch, H. Korkusuz, F. Grünwald, 131I- and 99mTc-uptake in focal thyroid autonomies. Development in Germany since the 1980s. Nuklearmedizin 55, 236–241 (2016) PubMed
26.
Zurück zum Zitat T.E. Hilditch, M.F. Dempsey, A.A. Bolster, R.M. McMenemin, N.S. Reed, Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur. J. Nucl. Med. 29, 783–788 (2002) T.E. Hilditch, M.F. Dempsey, A.A. Bolster, R.M. McMenemin, N.S. Reed, Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur. J. Nucl. Med. 29, 783–788 (2002)
27.
Zurück zum Zitat W. Lees, R. Mansberg, J. Roberts, J. Towson, E. Chua, J. Turtle, The clinical effects of thyroid stunning after diagnostic whole body scanning with 185 MBq 131I. Eur. J. Nucl. Med. 29, 1421–1427 (2002) W. Lees, R. Mansberg, J. Roberts, J. Towson, E. Chua, J. Turtle, The clinical effects of thyroid stunning after diagnostic whole body scanning with 185 MBq 131I. Eur. J. Nucl. Med. 29, 1421–1427 (2002)
28.
Zurück zum Zitat F.A. Verburg, R.B. Verkooijen, M.P. Stokkel, J.W. van Isselt, The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin 48, 138–142 (2009) PubMed F.A. Verburg, R.B. Verkooijen, M.P. Stokkel, J.W. van Isselt, The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin 48, 138–142 (2009) PubMed
29.
Zurück zum Zitat T. Bajén, S. Mañé, A. Muñoz, J.R. García, Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J. Nucl. Med. 41, 2038–2042 (2000) PubMed T. Bajén, S. Mañé, A. Muñoz, J.R. García, Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J. Nucl. Med. 41, 2038–2042 (2000) PubMed
30.
Zurück zum Zitat I.R. McDougall, 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl. Med. Commun. 18, 505–512 (1997) PubMed I.R. McDougall, 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl. Med. Commun. 18, 505–512 (1997) PubMed
31.
Zurück zum Zitat E. Wudel, K.Koppenhagen, The stunned thyroid? Veränderte Radiojodkinetik der NACH-THERAPIE bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 34, A166 (1995) E. Wudel, K.Koppenhagen, The stunned thyroid? Veränderte Radiojodkinetik der NACH-THERAPIE bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 34, A166 (1995)
32.
Zurück zum Zitat T. Krohn, P.T. Meyer, C. Ocklenburg, D. Knollmann, B. Nowak, W.M. Schaefer, Stunning in radioiodine therapy of benign thyroid disease. Quantification therapeutic relevance. Nuklearmedizin 47, 248–254 (2008) PubMed T. Krohn, P.T. Meyer, C. Ocklenburg, D. Knollmann, B. Nowak, W.M. Schaefer, Stunning in radioiodine therapy of benign thyroid disease. Quantification therapeutic relevance. Nuklearmedizin 47, 248–254 (2008) PubMed
33.
Zurück zum Zitat O. Sabri, M. Zimny, M. Schreckenberger, A. Meyer-Oelmann, P. Reinartz, U. Buell, Does thyroid stunning exist? A model with benign thyroid disease. Eur. J. Nucl. Med. 27, 1591–1597 (2000) PubMed O. Sabri, M. Zimny, M. Schreckenberger, A. Meyer-Oelmann, P. Reinartz, U. Buell, Does thyroid stunning exist? A model with benign thyroid disease. Eur. J. Nucl. Med. 27, 1591–1597 (2000) PubMed
34.
Zurück zum Zitat C.H. Kao, T.C. Yen, Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 37, 23–25 (1998) C.H. Kao, T.C. Yen, Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 37, 23–25 (1998)
35.
Zurück zum Zitat O. Dohan, A. de la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C.S. Ginter, N. Carrasco, The sodium/iodine symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 24, 48–77 (2003) PubMed O. Dohan, A. de la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C.S. Ginter, N. Carrasco, The sodium/iodine symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 24, 48–77 (2003) PubMed
36.
Zurück zum Zitat J.P. Muratet, A. Daver, J.F. Minier, F. Larra, Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J. Nucl. Med. 39, 1546–1550 (1998) PubMed J.P. Muratet, A. Daver, J.F. Minier, F. Larra, Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J. Nucl. Med. 39, 1546–1550 (1998) PubMed
37.
Zurück zum Zitat H.M. Park, O.W. Perkins, J.W. Edmondson, R.B. Schnute, A. Manatunga, Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 4, 49–54 (1994) PubMed H.M. Park, O.W. Perkins, J.W. Edmondson, R.B. Schnute, A. Manatunga, Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 4, 49–54 (1994) PubMed
38.
Zurück zum Zitat M. Nordén Lyckesvärd, N. Kapoor, C. Ingeson-Carlsson, T. Carlsson, J.O. Karlsson, P. Postgård, J. Himmelman, E. Forssell-Aronsson, O. Hammarsten, M. Nilsson, Linking loss of sodium-iodine symporter expression to DNA damage. Exp. Cell Res. 344, 120–131 (2016) M. Nordén Lyckesvärd, N. Kapoor, C. Ingeson-Carlsson, T. Carlsson, J.O. Karlsson, P. Postgård, J. Himmelman, E. Forssell-Aronsson, O. Hammarsten, M. Nilsson, Linking loss of sodium-iodine symporter expression to DNA damage. Exp. Cell Res. 344, 120–131 (2016)
39.
Zurück zum Zitat C. Lundh, M.M. Nordén, M. Nilsson, E. Forssell-Aronsson, Reduced iodine transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J. Nucl. Med. 48, 481–486 (2007) PubMed C. Lundh, M.M. Nordén, M. Nilsson, E. Forssell-Aronsson, Reduced iodine transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J. Nucl. Med. 48, 481–486 (2007) PubMed
40.
Zurück zum Zitat R.K. DeMott, R.T. Mulcahy, K.H. Clifton, The survival of thyroid cells following irradiation: a directly generated single-dose survival curve. Radiat. Res. 77, 395–403 (1979) PubMed R.K. DeMott, R.T. Mulcahy, K.H. Clifton, The survival of thyroid cells following irradiation: a directly generated single-dose survival curve. Radiat. Res. 77, 395–403 (1979) PubMed
41.
Zurück zum Zitat J. Halstenberg, W.T. Kranert, H. Korkusuz, A. Mayer, H. Ackermann, F. Grünwald, C. Happel, Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves’ disease. Nuklearmedizin 57, 43–49 (2018) PubMed J. Halstenberg, W.T. Kranert, H. Korkusuz, A. Mayer, H. Ackermann, F. Grünwald, C. Happel, Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves’ disease. Nuklearmedizin 57, 43–49 (2018) PubMed
42.
Zurück zum Zitat S. Park, E. Song, H. Oh, M. Kim, M.J. Jeon, W.G. Kim, T.Y. Kim, Y.K. Shong, D.M. Kim, W.B. Kim, When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued? Endocrine 65, 348–356 (2019) PubMed S. Park, E. Song, H. Oh, M. Kim, M.J. Jeon, W.G. Kim, T.Y. Kim, Y.K. Shong, D.M. Kim, W.B. Kim, When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued? Endocrine 65, 348–356 (2019) PubMed
43.
Zurück zum Zitat D.S. Cooper, L.H. Duntas, Thyroid hormone therapy: past, present, and future. Endocrine 66, 1–2 (2019) PubMed D.S. Cooper, L.H. Duntas, Thyroid hormone therapy: past, present, and future. Endocrine 66, 1–2 (2019) PubMed
44.
Zurück zum Zitat S.M. McLachlan, B. Rapoport, A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease. Endocrine 66, 137–148 (2019) PubMed S.M. McLachlan, B. Rapoport, A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease. Endocrine 66, 137–148 (2019) PubMed
45.
Zurück zum Zitat M.K. Chen, M. Yasrebi, J. Samii, L.H. Staib, I. Doddamane, D.W. Cheng, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid 22, 304–309 (2012) PubMed M.K. Chen, M. Yasrebi, J. Samii, L.H. Staib, I. Doddamane, D.W. Cheng, The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid 22, 304–309 (2012) PubMed
46.
Zurück zum Zitat F.A. Leger, M. Izembart, F. Dagousset, L. Barritault, G. Baillet, A. Chevalier, J. Clerc, Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur. J. Nucl. Med. 25, 242–246 (1998) PubMed F.A. Leger, M. Izembart, F. Dagousset, L. Barritault, G. Baillet, A. Chevalier, J. Clerc, Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur. J. Nucl. Med. 25, 242–246 (1998) PubMed
47.
Zurück zum Zitat A. Siddiqi, R.R. Foley, K.E. Britton, A. Sibtain, P.N. Plowman, A.B. Grossman, J.P. Monson, G.M. Besser, The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin. Endocrinol. 55, 515–521 (2001) A. Siddiqi, R.R. Foley, K.E. Britton, A. Sibtain, P.N. Plowman, A.B. Grossman, J.P. Monson, G.M. Besser, The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin. Endocrinol. 55, 515–521 (2001)
48.
Zurück zum Zitat F.A. Verburg, M. Schmidt, M.C. Kreissl, F. Grünwald, M. Lassmann, H. Hänscheid, M. Hohberg, M. Luster, M. Dietlein, Verfahrensanweisung für die Iod-131 Ganzkörperszintigrafie beim differenzierten Schilddrüsenkarzinom (Version 5). Nuklearmedizin 58, 228–241 (2019) PubMed F.A. Verburg, M. Schmidt, M.C. Kreissl, F. Grünwald, M. Lassmann, H. Hänscheid, M. Hohberg, M. Luster, M. Dietlein, Verfahrensanweisung für die Iod-131 Ganzkörperszintigrafie beim differenzierten Schilddrüsenkarzinom (Version 5). Nuklearmedizin 58, 228–241 (2019) PubMed
49.
Zurück zum Zitat E.B. Silberstein, Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J. Nucl. Med. 48, 1043–1046 (2007) PubMed E.B. Silberstein, Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J. Nucl. Med. 48, 1043–1046 (2007) PubMed
50.
Zurück zum Zitat C. Lundh, U. Lindencrona, P. Postgård, T. Carlsson, M. Nilsson, E. Forssell-Aronsson, Radiation-induced thyroid stunning: differential effects of 123I, 131I, 99mTc and 211At on iodide transport and NIS mRNA expression in cultured thyroid cells. J. Nucl. Med. 50, 1161–1167 (2009) PubMed C. Lundh, U. Lindencrona, P. Postgård, T. Carlsson, M. Nilsson, E. Forssell-Aronsson, Radiation-induced thyroid stunning: differential effects of 123I, 131I, 99mTc and 211At on iodide transport and NIS mRNA expression in cultured thyroid cells. J. Nucl. Med. 50, 1161–1167 (2009) PubMed
51.
Zurück zum Zitat Y.L. Heo, H.C. Song, MinJJ: thyroid stunning induced by I-123 scan in postoperative patients with papillary thyroid cancer: comparison with I-131 scan. J. Nucl. Med. 46, 310P (2005) Y.L. Heo, H.C. Song, MinJJ: thyroid stunning induced by I-123 scan in postoperative patients with papillary thyroid cancer: comparison with I-131 scan. J. Nucl. Med. 46, 310P (2005)
52.
Zurück zum Zitat N.A. Damle, C. Bal, S. Ballal, Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: critical importance of interval between the two scans. Indian J. Endocrinol. Metab. 16, 477–478 (2012) PubMedPubMedCentral N.A. Damle, C. Bal, S. Ballal, Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: critical importance of interval between the two scans. Indian J. Endocrinol. Metab. 16, 477–478 (2012) PubMedPubMedCentral
53.
Zurück zum Zitat D. Albano, M.B. Panarotto, R. Durmo, C. Rodella, F. Bertagna, R. Giubbini, Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer. Endocrine 63, 79–86 (2019) PubMed D. Albano, M.B. Panarotto, R. Durmo, C. Rodella, F. Bertagna, R. Giubbini, Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer. Endocrine 63, 79–86 (2019) PubMed
54.
Zurück zum Zitat F. Jerkovich, M.G.G. Falcone, F. Pitoia, The experience of an endorcinology division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 64, 632–638 (2019) PubMed F. Jerkovich, M.G.G. Falcone, F. Pitoia, The experience of an endorcinology division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 64, 632–638 (2019) PubMed
55.
Zurück zum Zitat A. Campennì, E. Amato, R. Laudicella, A. Alibrandi, D. Cardile, S.A. Pignata, F. Trimarchi, R.M. Ruggeri, L. Auditore, S. Baldari, Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose. Endocrine 65, 132–137 (2019) PubMed A. Campennì, E. Amato, R. Laudicella, A. Alibrandi, D. Cardile, S.A. Pignata, F. Trimarchi, R.M. Ruggeri, L. Auditore, S. Baldari, Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose. Endocrine 65, 132–137 (2019) PubMed
56.
Zurück zum Zitat H. Hänscheid, C. Canzi, W. Eschner, G. Flux, M. Luster, L. Strigari, M. Lassmann, EANM dosimetry commitee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimtery prior radioiodine therapy of benign thyroid diseases. Eur. J. Nucl. Med. Mol. Imaging 40, 1126–1134 (2013) PubMed H. Hänscheid, C. Canzi, W. Eschner, G. Flux, M. Luster, L. Strigari, M. Lassmann, EANM dosimetry commitee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimtery prior radioiodine therapy of benign thyroid diseases. Eur. J. Nucl. Med. Mol. Imaging 40, 1126–1134 (2013) PubMed
57.
Zurück zum Zitat T. Krohn, F.F. Behrendt, A. Heinzel, B. Müller, F.M. Mottaghy, F.A. Verburg, Pretherapeutic dosimetry before 131I therapy of benign thyroid diseases—a clinical practice assessment of dosimetric parameters. Nuklearmedizin 54, 131–136 (2015) PubMed T. Krohn, F.F. Behrendt, A. Heinzel, B. Müller, F.M. Mottaghy, F.A. Verburg, Pretherapeutic dosimetry before 131I therapy of benign thyroid diseases—a clinical practice assessment of dosimetric parameters. Nuklearmedizin 54, 131–136 (2015) PubMed
Metadaten
Titel
Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases
verfasst von
C. Happel
W. T. Kranert
D. Gröner
B. Bockisch
A. Sabet
I. Vardarli
R. Görges
K. Herrmann
F. Grünwald
Publikationsdatum
16.03.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02258-9

Weitere Artikel der Ausgabe 2/2020

Endocrine 2/2020 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.